Summary by Futu AI
AbbVie Inc. has released preliminary financial results for the third quarter of 2024, including the impact of acquired IPR&D and milestones expense. The company reported an expense of $82 million on a pre-tax basis, which is expected to negatively affect both GAAP and non-GAAP diluted earnings per share by $0.04. AbbVie's third quarter results have not been finalized and are subject to financial statement closing procedures. The company's full-year 2024 adjusted diluted earnings per share guidance, including the third quarter expense, is projected to be between $10.67 and $10.87. The third quarter adjusted diluted earnings per share guidance is estimated to be between $2.88 and $2.92, reflecting the incurred expense. AbbVie has previously announced that its adjusted diluted earnings per share guidance for 2024 would exclude the impact of any acquired IPR&D and milestones expense beyond the second quarter. The company cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
